The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease
Identifieur interne : 001075 ( Istex/Curation ); précédent : 001074; suivant : 001076The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease
Auteurs : V. Papazian [Australie] ; T. Jackson [Australie] ; T. Pham [Australie] ; X. Liu [Australie] ; I. Greguric [Australie] ; C. Loc'H [France] ; C. Rowe [Australie] ; V. Villemagne [Australie] ; C. L. Masters [Australie] ; A. Katsifis [Australie]Source :
- Journal of Labelled Compounds and Radiopharmaceuticals [ 0362-4803 ] ; 2005-06.
Descripteurs français
- Wicri :
- topic : Droit d'auteur, éthanol.
English descriptors
- KwdEn :
- Analytical hplc, Benzyl, Benzyl alcohol, Biol chem, Chemical purity, Clinical investigations, Cloxyquin, Compd, Copyright, Ethanol, Glass vial, Hplc, Hydrogen peroxide, Imaging disease, Iodogen, John wiley sons, Label compd radiopharm, Lipophilicity, Mmol, Mobile phase, Naoh, Papazian, Peracetic acid, Quality control, Radioactivity detector, Radiochemical, Radiochemical purity, Radiochemical yields, Radiolabelling, Radiolabelling yields, Radiopharm, Radiopharmaceutical, Radiopharmaceutical preparation, Reaction mixture, Retention time, Room temperature.
- Teeft :
- Analytical hplc, Benzyl, Benzyl alcohol, Biol chem, Chemical purity, Clinical investigations, Cloxyquin, Compd, Copyright, Ethanol, Glass vial, Hplc, Hydrogen peroxide, Imaging disease, Iodogen, John wiley sons, Label compd radiopharm, Lipophilicity, Mmol, Mobile phase, Naoh, Papazian, Peracetic acid, Quality control, Radioactivity detector, Radiochemical, Radiochemical purity, Radiochemical yields, Radiolabelling, Radiolabelling yields, Radiopharm, Radiopharmaceutical, Radiopharmaceutical preparation, Reaction mixture, Retention time, Room temperature.
Abstract
Clioquinol or 5‐chloro‐7‐iodo‐8‐hydroxyquinoline (CQ) is a lipophilic hydroxyquinoline currently under investigation for the treatment of Alzheimer's disease by targeted copper and zinc chelation. CQ was radiolabelled with no‐carrier‐added iodine‐123/125 to give high specific activity analogs for SPECT imaging and biochemical studies. 123I‐clioquinol (123I‐CQ) was prepared by direct iodination of the activated hydroxyquinoline using a variety of oxidants. Highest yields (>85%) and purity were obtained when chloramine‐T or iodogen at pH 4–5 was used. Large‐scale radiolabelled 123I‐CQ was purified by reverse‐phase HPLC using a C‐18 small ‘Rocket®’ column. The radiochemical purity of 123I‐CQ as assessed by analytical HPLC was 99.1±0.6% (n = 9) with specific activity higher than 3 GBq/nmol for 123I‐CQ and 80 MBq/nmol for 125I‐CQ. The total preparation time was 40 min and starting from 3.7 GBq of iodine‐123, more than 2.5 GBq of formulated 123I‐CQ as radiopharmaceutical was available for clinical investigations. Using the same method of preparation, 125I‐CQ was produced in radiochemical and chemical purity higher than 97% with a specific activity of 80 MBq/nmol. Copyright © 2005 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/jlcr.942
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001075
Links to Exploration step
ISTEX:58C475AC1413BF5F9BDA2721A5A046F482C810A5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease</title><author><name sortKey="Papazian, V" sort="Papazian, V" uniqKey="Papazian V" first="V." last="Papazian">V. Papazian</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, T" sort="Jackson, T" uniqKey="Jackson T" first="T." last="Jackson">T. Jackson</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Pham, T" sort="Pham, T" uniqKey="Pham T" first="T." last="Pham">T. Pham</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Liu, X" sort="Liu, X" uniqKey="Liu X" first="X." last="Liu">X. Liu</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Greguric, I" sort="Greguric, I" uniqKey="Greguric I" first="I." last="Greguric">I. Greguric</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Loc H, C" sort="Loc H, C" uniqKey="Loc H C" first="C." last="Loc'H">C. Loc'H</name><affiliation wicri:level="1"><mods:affiliation>Service Hospitalier Frederic Joliot, CEA/DSV/DRM, F‐91406 Orsay, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Hospitalier Frederic Joliot, CEA/DSV/DRM, F‐91406 Orsay</wicri:regionArea></affiliation></author><author><name sortKey="Rowe, C" sort="Rowe, C" uniqKey="Rowe C" first="C." last="Rowe">C. Rowe</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084</wicri:regionArea></affiliation></author><author><name sortKey="Villemagne, V" sort="Villemagne, V" uniqKey="Villemagne V" first="V." last="Villemagne">V. Villemagne</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084</wicri:regionArea></affiliation></author><author><name sortKey="Masters, C L" sort="Masters, C L" uniqKey="Masters C" first="C. L." last="Masters">C. L. Masters</name><affiliation wicri:level="1"><mods:affiliation>Department of Pathology, The University of Melbourne Parkville, Vic. 3010, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Pathology, The University of Melbourne Parkville, Vic. 3010</wicri:regionArea></affiliation></author><author><name sortKey="Katsifis, A" sort="Katsifis, A" uniqKey="Katsifis A" first="A." last="Katsifis">A. Katsifis</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: akx@ansto.gov.au</mods:affiliation><country wicri:rule="url">Australie</country></affiliation><affiliation wicri:level="1"><mods:affiliation>Correspondence address: Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Private Mail Bag 1, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Correspondence address: Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Private Mail Bag 1, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:58C475AC1413BF5F9BDA2721A5A046F482C810A5</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/jlcr.942</idno><idno type="url">https://api.istex.fr/document/58C475AC1413BF5F9BDA2721A5A046F482C810A5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001075</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001075</idno><idno type="wicri:Area/Istex/Curation">001075</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The preparation of <hi rend="superscript">123/125</hi>I‐clioquinol for the study of Aβ protein in Alzheimer's disease</title><author><name sortKey="Papazian, V" sort="Papazian, V" uniqKey="Papazian V" first="V." last="Papazian">V. Papazian</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, T" sort="Jackson, T" uniqKey="Jackson T" first="T." last="Jackson">T. Jackson</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Pham, T" sort="Pham, T" uniqKey="Pham T" first="T." last="Pham">T. Pham</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Liu, X" sort="Liu, X" uniqKey="Liu X" first="X." last="Liu">X. Liu</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Greguric, I" sort="Greguric, I" uniqKey="Greguric I" first="I." last="Greguric">I. Greguric</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author><author><name sortKey="Loc H, C" sort="Loc H, C" uniqKey="Loc H C" first="C." last="Loc'H">C. Loc'H</name><affiliation wicri:level="1"><mods:affiliation>Service Hospitalier Frederic Joliot, CEA/DSV/DRM, F‐91406 Orsay, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Hospitalier Frederic Joliot, CEA/DSV/DRM, F‐91406 Orsay</wicri:regionArea></affiliation></author><author><name sortKey="Rowe, C" sort="Rowe, C" uniqKey="Rowe C" first="C." last="Rowe">C. Rowe</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084</wicri:regionArea></affiliation></author><author><name sortKey="Villemagne, V" sort="Villemagne, V" uniqKey="Villemagne V" first="V." last="Villemagne">V. Villemagne</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Nuclear medicine Centre for PET, Austin Hospital, Studley Rd, Heidelberg, Vic. 3084</wicri:regionArea></affiliation></author><author><name sortKey="Masters, C L" sort="Masters, C L" uniqKey="Masters C" first="C. L." last="Masters">C. L. Masters</name><affiliation wicri:level="1"><mods:affiliation>Department of Pathology, The University of Melbourne Parkville, Vic. 3010, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Pathology, The University of Melbourne Parkville, Vic. 3010</wicri:regionArea></affiliation></author><author><name sortKey="Katsifis, A" sort="Katsifis, A" uniqKey="Katsifis A" first="A." last="Katsifis">A. Katsifis</name><affiliation wicri:level="1"><mods:affiliation>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: akx@ansto.gov.au</mods:affiliation><country wicri:rule="url">Australie</country></affiliation><affiliation wicri:level="1"><mods:affiliation>Correspondence address: Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Private Mail Bag 1, Menai, Sydney, NSW 2234, Australia</mods:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Correspondence address: Radiopharmaceuticals Division R&D, Australian Nuclear Science & Technology Organisation, Private Mail Bag 1, Menai, Sydney, NSW 2234</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Labelled Compounds and Radiopharmaceuticals</title><title level="j" type="alt">JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS</title><idno type="ISSN">0362-4803</idno><idno type="eISSN">1099-1344</idno><imprint><biblScope unit="vol">48</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="473">473</biblScope><biblScope unit="page" to="484">484</biblScope><biblScope unit="page-count">12</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2005-06">2005-06</date></imprint><idno type="ISSN">0362-4803</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0362-4803</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analytical hplc</term><term>Benzyl</term><term>Benzyl alcohol</term><term>Biol chem</term><term>Chemical purity</term><term>Clinical investigations</term><term>Cloxyquin</term><term>Compd</term><term>Copyright</term><term>Ethanol</term><term>Glass vial</term><term>Hplc</term><term>Hydrogen peroxide</term><term>Imaging disease</term><term>Iodogen</term><term>John wiley sons</term><term>Label compd radiopharm</term><term>Lipophilicity</term><term>Mmol</term><term>Mobile phase</term><term>Naoh</term><term>Papazian</term><term>Peracetic acid</term><term>Quality control</term><term>Radioactivity detector</term><term>Radiochemical</term><term>Radiochemical purity</term><term>Radiochemical yields</term><term>Radiolabelling</term><term>Radiolabelling yields</term><term>Radiopharm</term><term>Radiopharmaceutical</term><term>Radiopharmaceutical preparation</term><term>Reaction mixture</term><term>Retention time</term><term>Room temperature</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Analytical hplc</term><term>Benzyl</term><term>Benzyl alcohol</term><term>Biol chem</term><term>Chemical purity</term><term>Clinical investigations</term><term>Cloxyquin</term><term>Compd</term><term>Copyright</term><term>Ethanol</term><term>Glass vial</term><term>Hplc</term><term>Hydrogen peroxide</term><term>Imaging disease</term><term>Iodogen</term><term>John wiley sons</term><term>Label compd radiopharm</term><term>Lipophilicity</term><term>Mmol</term><term>Mobile phase</term><term>Naoh</term><term>Papazian</term><term>Peracetic acid</term><term>Quality control</term><term>Radioactivity detector</term><term>Radiochemical</term><term>Radiochemical purity</term><term>Radiochemical yields</term><term>Radiolabelling</term><term>Radiolabelling yields</term><term>Radiopharm</term><term>Radiopharmaceutical</term><term>Radiopharmaceutical preparation</term><term>Reaction mixture</term><term>Retention time</term><term>Room temperature</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Droit d'auteur</term><term>éthanol</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clioquinol or 5‐chloro‐7‐iodo‐8‐hydroxyquinoline (CQ) is a lipophilic hydroxyquinoline currently under investigation for the treatment of Alzheimer's disease by targeted copper and zinc chelation. CQ was radiolabelled with no‐carrier‐added iodine‐123/125 to give high specific activity analogs for SPECT imaging and biochemical studies. 123I‐clioquinol (123I‐CQ) was prepared by direct iodination of the activated hydroxyquinoline using a variety of oxidants. Highest yields (>85%) and purity were obtained when chloramine‐T or iodogen at pH 4–5 was used. Large‐scale radiolabelled 123I‐CQ was purified by reverse‐phase HPLC using a C‐18 small ‘Rocket®’ column. The radiochemical purity of 123I‐CQ as assessed by analytical HPLC was 99.1±0.6% (n = 9) with specific activity higher than 3 GBq/nmol for 123I‐CQ and 80 MBq/nmol for 125I‐CQ. The total preparation time was 40 min and starting from 3.7 GBq of iodine‐123, more than 2.5 GBq of formulated 123I‐CQ as radiopharmaceutical was available for clinical investigations. Using the same method of preparation, 125I‐CQ was produced in radiochemical and chemical purity higher than 97% with a specific activity of 80 MBq/nmol. Copyright © 2005 John Wiley & Sons, Ltd.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001075 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001075 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:58C475AC1413BF5F9BDA2721A5A046F482C810A5
|texte= The preparation of 123/125I‐clioquinol for the study of Aβ protein in Alzheimer's disease
}}
| This area was generated with Dilib version V0.6.33. |  |